Genprex, Inc.
No SEC Form 4 filings for $GNPX in the last 30 days.
See all $GNPX insider activity →Genprex (NASDAQ:GNPX) said it is collaborating with Roche Diagnostics to validate NSCLC patient-selection biomarkers using Roche’s TROP2 antibody. Genprex cited data linking high TROP2 H-scores and low PTEN H-scores with longer progression-free survival. Roche will run assay validation, expected by end-2026, for Genprex’s NSCLC trials.
Genprex (GNPX) shares fell 12.4% in pre-open trading after a Roche Diagnostics collaboration announcement. The deal aims to validate TROP2 and PTEN biomarkers for patient selection in non-small cell lung cancer trials, building on Genprex’s Reqorsa Gene Therapy preclinical findings. The stock initially rose about 3% before reversing; no analyst or insider changes were cited.
Genprex Inc. (NASDAQ:GNPX) shares rose about 3% after it said Roche Diagnostics will collaborate to validate TROP2 biomarker assays for patient selection in non-small cell lung cancer trials. Roche will use its TROP2 antibody, also used in an FDA-designated companion diagnostic. Genprex expects validation by late 2026, then integration into its NSCLC program.
Over the past 7 days, alphai's AI scored 3 news stories mentioning GNPX (Genprex, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 1 bearish.
Recent GNPX coverage spans financial news, market movers and technology.
The deal is a concrete execution milestone for Genprex’s biomarker strategy in NSCLC, potentially improving trial enrollment efficiency and patient stratification.
The article frames a sentiment reversal in a highly speculative micro-cap after the Roche biomarker deal failed to hold the initial bid.
The Roche validation work is a concrete step toward integrating TROP2/PTEN biomarker stratification into Genprex’s NSCLC program, supporting near-term sentiment.
This is an SEC disclosure of governance/compensation plan changes, not an operational or financial datapoint.
The reported ownership increase suggests institutional or significant investor interest in GNPX, potentially signaling confidence or strategic positioning.
alphai scores every news story that mentions GNPX with an AI model for sentiment and relevance, and aggregates insider trades from Genprex, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Genprex (NASDAQ:GNPX) said it is collaborating with Roche Diagnostics to validate NSCLC patient-selection biomarkers using Roche’s TROP2 antibody. Genprex cited data linking high TROP2 H-scores and low PTEN H-scores with longer progression-free survival. Roche will run assay validation, expected by end-2026, for Genprex’s NSCLC trials.
2 min readGenprex (GNPX) shares fell 12.4% in pre-open trading after a Roche Diagnostics collaboration announcement. The deal aims to validate TROP2 and PTEN biomarkers for patient selection in non-small cell lung cancer trials, building on Genprex’s Reqorsa Gene Therapy preclinical findings. The stock initially rose about 3% before reversing; no analyst or insider changes were cited.
3 min readGenprex Inc. (NASDAQ:GNPX) shares rose about 3% after it said Roche Diagnostics will collaborate to validate TROP2 biomarker assays for patient selection in non-small cell lung cancer trials. Roche will use its TROP2 antibody, also used in an FDA-designated companion diagnostic. Genprex expects validation by late 2026, then integration into its NSCLC program.
4 min readGenprex, Inc. (GNPX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ex_976935.htm EXHIBIT 10.1 ex_976935.htm Exhibit 10.1 GENPREX, INC. 2018 EQUITY INCENTIVE PLAN As Amended and Restated Effective April 15, 2026 (the “ Restatement Date ” ) 1. Purposes of the Plan. The purposes of this Plan are to attract and retain personnel for positio
2 min readAyrton Capital LLC, Alto Opportunity Master Fund (Segregated Master Portfolio B), and Waqas Khatri have reported beneficial ownership of 249,788 shares of Genprex, Inc. common stock, exercisable through warrants. This represents a 2.69% stake, based on 9,044,856 shares outstanding as of March 27, 2026, and is subject to a 9.99% beneficial ownership blocker. The filing is a routine disclosure of derivative-based ownership, as the holdings are under 5% and include an ownership cap.
2 min readThis article highlights three oversold healthcare stocks – Medtronic (MDT), Option Care Health (OPCH), and Genprex (GNPX) – that could see upward movement in Q2, based on a Relative Strength Index (RSI) near or below 30. It details recent company news, stock performance, and RSI values for each, suggesting an opportunity for investors to consider undervalued companies. The piece utilizes Benzinga Pro data to identify these potential breakouts.
4 min readGenprex (NASDAQ: GNPX) is seeking stockholder approval for several key proposals at its virtual annual meeting on June 18, 2026, including the election of two Class III directors, ratification of its independent auditor, and an advisory vote on executive compensation. Critically, the company also proposes to amend and restate its 2018 Equity Incentive Plan and authorize a reverse stock split at a ratio between 1-for-5 and 1-for-50, which the board could implement anytime before December 31, 2027. These capital structure changes aim to provide flexibility for future equity issuance and maintain NASDAQ listing compliance.
3 min readGenprex Inc. ( NASDAQ:GNPX ) shares rose 41.39% to $0.36 in after-hours trading on Tuesday. Check out the current price of GNPX stock here.
3 min read
